Table 4.
Values of the EuroQol‐5D (EQ‐5D) utility scores and proportions of patients reporting any problem in the EQ‐5D dimensions in patients with psoriasis at different follow‐up times (Intention‐to‐treat analysis)
| All patients | Etanercept | Adalimumab | Ustekinumab | |
|---|---|---|---|---|
| EQ‐5D utility score, median [IQR] (n) | ||||
| Baseline | 0·73 [0·59–0·80] (1618) | 0·73 [0·52–0·80] (391) | 0·73 [0·62–0·80] (907) | 0·73 [0·59–0·80] (320) |
| 6 months | 0·85 [0·69–1·00] (1358)** | 0·80 [0·69–1·00] (316)** | 0·85 [0·73–1·00] (774)** | 0·85 [0·67–1·00] (268)** |
| Change from baseline to 6 months | 0·07 [0·00–0·27] (1358) | 0·07 [0·00–0·24] (316) | 0·11 [0·00–0·27] (774) | 0·07 [0·00–0·24] (268) |
| 12 months | 0·85 [0·69–1·00] (1108)** | 0·80 [0·69–1·00] (277)** | 0·85 [0·71–1·00] (604)** | 0·85 [0·66–1·00] (227)** |
| Change from baseline to 12 months | 0·10 [0·00–0·28] (1108) | 0·12 [0·00–0·28] (277) | 0·11 [0·00–0·27] (604) | 0·07 [0·00–0·28] (227) |
| EQ‐5D dimensions, n (%) | ||||
| Mobility | ||||
| Baseline | 555 (34·3) | 140 (35·8) | 299 (33·0) | 116 (36·3) |
| 6 months | 365 (26·9)** | 88 (27·9)* | 190 (24·8)** | 85 (31·7)* |
| 12 months | 327 (29·5)** | 85 (30·7)* | 163 (27·0)* | 79 (34·8) |
| Self‐care | ||||
| Baseline | 291 (18·0) | 77 (19·7) | 147 (16·2) | 67 (20·9) |
| 6 months | 170 (12·5)** | 41 (13·0)* | 81 (10·5)** | 48 (17·9) |
| 12 months | 149 (13·5)** | 32 (11·6)** | 74 (12·3)* | 43 (18·9) |
| Usual activities | ||||
| Baseline | 700 (43·3) | 181 (46·3) | 381 (42·0) | 138 (43·1) |
| 6 months | 339 (25·0)** | 78 (24·7)** | 182 (23·5)** | 79 (29·5)** |
| 12 months | 279 (25·2)** | 70 (25·3)** | 141 (23·3)** | 68 (30·0)** |
| Pain/discomfort | ||||
| Baseline | 1206 (74·5) | 296 (75·7) | 672 (74·1) | 238 (74·4) |
| 6 months | 606 (44·6)** | 158 (50·0)** | 329 (42·5)** | 119 (44·4)** |
| 12 months | 501 (45·2)** | 139 (50·2)** | 255 (42·2)** | 107 (47·1)** |
| Anxiety/depression | ||||
| Baseline | 826 (51·1) | 215 (55·0) | 453 (49·9) | 158 (49·4) |
| 6 months | 461 (34·0)** | 123 (38·9)** | 252 (32·6)** | 86 (32·1)** |
| 12 months | 361 (32·6)** | 101 (36·5)** | 187 (31·0)** | 73 (32·2)** |
IQR, interquartile range. *P < 0·05 (calculated for each follow‐up vs. baseline within the same cohort). **P < 0·001 (calculated for each follow‐up vs. baseline within the same cohort).